The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
MedWatch The FDA Safety Information and Adverse Event Reporting Program
Important safety-related changes to the prescribing information concerning the use of Xeloda in patients with renal impairment at baseline.
[November 28, 2000 - Letter - Roche Pharmaceuticals][November 28, 2000 - Package Insert - Roche Pharmaceuticals]
Page Last Updated: 08/14/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English